Sarepta sees early success with RNAi drugs from Arrowhead

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two ...
24/7 Wall St.

Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?

Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...
The Pharma Letter

Viz.ai teams up with Alnylam in cardiac amyloidosis

AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm ...

Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has entered new collaborations with Viz.ai and the American Heart Association to ...